Nonsteroidal therapy of sarcoidosis

Peter Korsten, Mehdi Mirsaeidi, Nadera J. Sweiss

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

PURPOSE OF REVIEW: None of the medications used in clinical practice to treat sarcoidosis have been approved by the regulatory authorities. Understanding how to use disease-modifying antisarcoid drugs, however, is essential for physicians treating patients with sarcoidosis. This review summarizes the recent studies of medications used for sarcoidosis with a focus on nonsteroidal therapies. Studies from 2006 to 2013 were considered for review to update clinicians on the most relevant literature published over the last few years. RECENT FINDINGS: Several recently published pieces of evidence have helped expand our ability to more appropriately sequence second-line and third-line therapies for sarcoidosis. For instance, methotrexate and azathioprine may be useful and well tolerated medications as second-line treatment. Mycophenolate mofetil might have a role in neurosarcoidosis. TNF-α blockers and other biologics seem to be well tolerated medications for the most severely affected patients. SUMMARY: Corticosteroids remain the first-line therapy for sarcoidosis as many patients never require treatment or only necessitate a short treatment duration. Second-line and third-line therapies described in this article should be used in patients with progressive or refractory disease or when life-threatening complications are evident at the time of presentation.

Original languageEnglish (US)
Pages (from-to)516-523
Number of pages8
JournalCurrent Opinion in Pulmonary Medicine
Volume19
Issue number5
DOIs
StatePublished - Sep 2013
Externally publishedYes

Fingerprint

Sarcoidosis
Therapeutics
Mycophenolic Acid
Azathioprine
Biological Products
Methotrexate
Adrenal Cortex Hormones
Physicians
Pharmaceutical Preparations

Keywords

  • corticosteroids
  • Disease-modifying antisarcoid drugs
  • Sarcoidosis
  • TNF-α inhibitor

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Nonsteroidal therapy of sarcoidosis. / Korsten, Peter; Mirsaeidi, Mehdi; Sweiss, Nadera J.

In: Current Opinion in Pulmonary Medicine, Vol. 19, No. 5, 09.2013, p. 516-523.

Research output: Contribution to journalArticle

Korsten, Peter ; Mirsaeidi, Mehdi ; Sweiss, Nadera J. / Nonsteroidal therapy of sarcoidosis. In: Current Opinion in Pulmonary Medicine. 2013 ; Vol. 19, No. 5. pp. 516-523.
@article{eed095c51f4d4dff9eacb8d3022c6748,
title = "Nonsteroidal therapy of sarcoidosis",
abstract = "PURPOSE OF REVIEW: None of the medications used in clinical practice to treat sarcoidosis have been approved by the regulatory authorities. Understanding how to use disease-modifying antisarcoid drugs, however, is essential for physicians treating patients with sarcoidosis. This review summarizes the recent studies of medications used for sarcoidosis with a focus on nonsteroidal therapies. Studies from 2006 to 2013 were considered for review to update clinicians on the most relevant literature published over the last few years. RECENT FINDINGS: Several recently published pieces of evidence have helped expand our ability to more appropriately sequence second-line and third-line therapies for sarcoidosis. For instance, methotrexate and azathioprine may be useful and well tolerated medications as second-line treatment. Mycophenolate mofetil might have a role in neurosarcoidosis. TNF-α blockers and other biologics seem to be well tolerated medications for the most severely affected patients. SUMMARY: Corticosteroids remain the first-line therapy for sarcoidosis as many patients never require treatment or only necessitate a short treatment duration. Second-line and third-line therapies described in this article should be used in patients with progressive or refractory disease or when life-threatening complications are evident at the time of presentation.",
keywords = "corticosteroids, Disease-modifying antisarcoid drugs, Sarcoidosis, TNF-α inhibitor",
author = "Peter Korsten and Mehdi Mirsaeidi and Sweiss, {Nadera J.}",
year = "2013",
month = "9",
doi = "10.1097/MCP.0b013e3283642ad0",
language = "English (US)",
volume = "19",
pages = "516--523",
journal = "Current Opinion in Pulmonary Medicine",
issn = "1070-5287",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Nonsteroidal therapy of sarcoidosis

AU - Korsten, Peter

AU - Mirsaeidi, Mehdi

AU - Sweiss, Nadera J.

PY - 2013/9

Y1 - 2013/9

N2 - PURPOSE OF REVIEW: None of the medications used in clinical practice to treat sarcoidosis have been approved by the regulatory authorities. Understanding how to use disease-modifying antisarcoid drugs, however, is essential for physicians treating patients with sarcoidosis. This review summarizes the recent studies of medications used for sarcoidosis with a focus on nonsteroidal therapies. Studies from 2006 to 2013 were considered for review to update clinicians on the most relevant literature published over the last few years. RECENT FINDINGS: Several recently published pieces of evidence have helped expand our ability to more appropriately sequence second-line and third-line therapies for sarcoidosis. For instance, methotrexate and azathioprine may be useful and well tolerated medications as second-line treatment. Mycophenolate mofetil might have a role in neurosarcoidosis. TNF-α blockers and other biologics seem to be well tolerated medications for the most severely affected patients. SUMMARY: Corticosteroids remain the first-line therapy for sarcoidosis as many patients never require treatment or only necessitate a short treatment duration. Second-line and third-line therapies described in this article should be used in patients with progressive or refractory disease or when life-threatening complications are evident at the time of presentation.

AB - PURPOSE OF REVIEW: None of the medications used in clinical practice to treat sarcoidosis have been approved by the regulatory authorities. Understanding how to use disease-modifying antisarcoid drugs, however, is essential for physicians treating patients with sarcoidosis. This review summarizes the recent studies of medications used for sarcoidosis with a focus on nonsteroidal therapies. Studies from 2006 to 2013 were considered for review to update clinicians on the most relevant literature published over the last few years. RECENT FINDINGS: Several recently published pieces of evidence have helped expand our ability to more appropriately sequence second-line and third-line therapies for sarcoidosis. For instance, methotrexate and azathioprine may be useful and well tolerated medications as second-line treatment. Mycophenolate mofetil might have a role in neurosarcoidosis. TNF-α blockers and other biologics seem to be well tolerated medications for the most severely affected patients. SUMMARY: Corticosteroids remain the first-line therapy for sarcoidosis as many patients never require treatment or only necessitate a short treatment duration. Second-line and third-line therapies described in this article should be used in patients with progressive or refractory disease or when life-threatening complications are evident at the time of presentation.

KW - corticosteroids

KW - Disease-modifying antisarcoid drugs

KW - Sarcoidosis

KW - TNF-α inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84881670568&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881670568&partnerID=8YFLogxK

U2 - 10.1097/MCP.0b013e3283642ad0

DO - 10.1097/MCP.0b013e3283642ad0

M3 - Article

C2 - 23884295

AN - SCOPUS:84881670568

VL - 19

SP - 516

EP - 523

JO - Current Opinion in Pulmonary Medicine

JF - Current Opinion in Pulmonary Medicine

SN - 1070-5287

IS - 5

ER -